Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000947871-24-000702
Filing Date
2024-08-15
Accepted
2024-08-15 17:01:28
Documents
1
Period of Report
2024-08-13

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 9546
  Complete submission text file 0000947871-24-000702.txt   12277
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Reporting) CIK: 0001055951 (see all company filings)

State of Incorp.: DE
Type: 4 | Act: 34 | File No.: 001-39264 | Film No.: 241213273

Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Issuer) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022 212-739-6491
OrbiMed Capital GP VII LLC (Reporting) CIK: 0001760648 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-39264 | Film No.: 241213272

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
OrbiMed Genesis GP LLC (Reporting) CIK: 0001808744 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-39264 | Film No.: 241213271